Tenaya Therapeutics, Inc. 8-K

What Happened
Tenaya Therapeutics announced on June 29, 2026 (8-K filing) that Eric Hyllengren will join the company as Chief Financial Officer on July 13, 2026 and will serve as the company’s Principal Financial Officer and Principal Accounting Officer beginning that date. Current interim Principal Financial Officer Faraz Ali and acting interim Principal Accounting Officer Tomohiro Higa will cease those interim duties immediately prior to Hyllengren’s start. The company filed the offer letter (dated June 18, 2026) and a press release regarding the appointment.

Key Details

• Start date: July 13, 2026. Offer letter dated June 18, 2026; 8-K filed June 29, 2026.
• Cash compensation: $490,000 annual base salary; target annual bonus = 40% of base salary.
• Equity grant (subject to board/committee approval): option to purchase 1,650,000 shares under the 2024 Inducement Plan; 10‑year term; exercise price = fair market value. Vesting: 25% at 1 year, then monthly thereafter (1/48th).
• Other: Eligible for the company’s Executive Change in Control Severance Plan and the company’s standard officer indemnification agreement.
• Background: Age 51; most recently CFO at Zura Bio Ltd. (July 2025–Apr 2026); seven years at Atara Biotherapeutics in finance and C-suite roles; earlier finance/business development roles at Amgen. Holds a B.B.A. (University of Notre Dame) and an M.B.A. (Kellogg).

Why It Matters
A permanent CFO appointment replaces interim coverage and clarifies who will lead finance and accounting functions—important for financial reporting, investor communication, and strategic execution. The compensation package (salary, bonus target, and a sizable stock option) aligns the new CFO’s incentives with stock performance and retention. Investors should note the timing of the hire (mid‑July) and the grant/approval mechanics, which may affect share-based expense and future disclosures.